Plasmid-Based Materials as Multiplex Quality Controls and Calibrators for Clinical Next- Generation Sequencing Assays  David J. Sims, Robin D. Harrington,

Slides:



Advertisements
Similar presentations
Comparison of Clinical Targeted Next-Generation Sequence Data from Formalin-Fixed and Fresh-Frozen Tissue Specimens  David H. Spencer, Jennifer K. Sehn,
Advertisements

Implementation of a Reliable Next-Generation Sequencing Strategy for Molecular Diagnosis of Dystrophinopathies  Melissa Alame, Delphine Lacourt, Reda.
Simultaneous Detection of Clinically Relevant Mutations and Amplifications for Routine Cancer Pathology  Marlous Hoogstraat, John W.J. Hinrichs, Nicolle.
Carol Beadling, Tanaya L. Neff, Michael C
A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors  Rajyalakshmi.
Assessing Copy Number Alterations in Targeted, Amplicon-Based Next-Generation Sequencing Data  Catherine Grasso, Timothy Butler, Katherine Rhodes, Michael.
Emily M. Kudalkar, Naif A. M
Single-Color Digital PCR Provides High-Performance Detection of Cancer Mutations from Circulating DNA  Christina Wood-Bouwens, Billy T. Lau, Christine.
Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe–Based Single-
A Method to Evaluate the Quality of Clinical Gene-Panel Sequencing Data for Single- Nucleotide Variant Detection  Chung Lee, Joon S. Bae, Gyu H. Ryu, Nayoung.
Methodologic Considerations in the Application of Next-Generation Sequencing of Human TRB Repertoires for Clinical Use  Liwen Xu, Xiaoqing You, PingPing.
High-Throughput, Multiplex Genotyping Directly from Blood or Dried Blood Spot without DNA Extraction for the Screening of Multiple G6PD Gene Variants.
Hendrikus J. Dubbink, Peggy N. Atmodimedjo, Ronald van Marion, Niels M
A Quantitative Allele-Specific PCR Test for the BRAF V600E Mutation Using a Single Heterozygous Control Plasmid for Quantitation  Philippe Szankasi, N.
Performance of Common Analysis Methods for Detecting Low-Frequency Single Nucleotide Variants in Targeted Next-Generation Sequence Data  David H. Spencer,
Suppression of Wild-Type Amplification by Selectivity Enhancing Agents in PCR Assays that Utilize SuperSelective Primers for the Detection of Rare Somatic.
Targeted, High-Depth, Next-Generation Sequencing of Cancer Genes in Formalin- Fixed, Paraffin-Embedded and Fine-Needle Aspiration Tumor Specimens  Andrew.
Robustness of Amplicon Deep Sequencing Underlines Its Utility in Clinical Applications  Vera Grossmann, Andreas Roller, Hans-Ulrich Klein, Sandra Weissmann,
Clinical Application of Picodroplet Digital PCR Technology for Rapid Detection of EGFR T790M in Next-Generation Sequencing Libraries and DNA from Limited.
Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal- Finding Clinical Trial  Chih-Jian Lih, Robin D. Harrington, David.
Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice  Stephan Bartels, Sascha Persing, Britta Hasemeier,
Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays 
Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management 
A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia  Ilaria.
Simultaneous Detection of Clinically Relevant Mutations and Amplifications for Routine Cancer Pathology  Marlous Hoogstraat, John W.J. Hinrichs, Nicolle.
Comparison of Allelic Discrimination by dHPLC, HRM, and TaqMan in the Detection of BRAF Mutation V600E  Pablo Carbonell, María C. Turpin, Daniel Torres-Moreno,
Clinical Relevance of Sensitive and Quantitative STAT3 Mutation Analysis Using Next- Generation Sequencing in T-Cell Large Granular Lymphocytic Leukemia 
Molecular Diagnosis of Autosomal Dominant Polycystic Kidney Disease Using Next- Generation Sequencing  Adrian Y. Tan, Alber Michaeel, Genyan Liu, Olivier.
Utilization of Whole-Exome Next-Generation Sequencing Variant Read Frequency for Detection of Lesion-Specific, Somatic Loss of Heterozygosity in a Neurofibromatosis.
Christopher R. Cabanski, Vincent Magrini, Malachi Griffith, Obi L
Donavan T. Cheng, Talia N. Mitchell, Ahmet Zehir, Ronak H
A Comprehensive Strategy for Accurate Mutation Detection of the Highly Homologous PMS2  Jianli Li, Hongzheng Dai, Yanming Feng, Jia Tang, Stella Chen,
Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid  Meenakshi Mehrotra, Rajesh.
Martin Steinau, Sonya S. Patel, Elizabeth R. Unger 
Robust Detection of DNA Hypermethylation of ZNF154 as a Pan-Cancer Locus with in Silico Modeling for Blood-Based Diagnostic Development  Gennady Margolin,
Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation 
Certified DNA Reference Materials to Compare HER2 Gene Amplification Measurements Using Next-Generation Sequencing Methods  Chih-Jian Lih, Han Si, Biswajit.
Eric Samorodnitsky, Jharna Datta, Benjamin M
High-Throughput and Sensitive Quantification of Circulating Tumor DNA by Microfluidic- Based Multiplex PCR and Next-Generation Sequencing  Yinghui Guan,
ColoSeq Provides Comprehensive Lynch and Polyposis Syndrome Mutational Analysis Using Massively Parallel Sequencing  Colin C. Pritchard, Christina Smith,
Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies  Michael J. Kluk, R. Coleman Lindsley,
Comprehensive Diagnostic Testing for Stereocilin
Evaluation of BRAF Mutation Testing Methodologies in Formalin-Fixed, Paraffin- Embedded Cutaneous Melanomas  Johanne Lade-Keller, Kirsten M. Rømer, Per.
Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid  Meenakshi Mehrotra, Rajesh.
Analytical Validation of Clinical Whole-Genome and Transcriptome Sequencing of Patient-Derived Tumors for Reporting Targetable Variants in Cancer  Kazimierz.
Detection of Mutations in Myeloid Malignancies through Paired-Sample Analysis of Microdroplet-PCR Deep Sequencing Data  Donavan T. Cheng, Janice Cheng,
Application of a BRAF Pyrosequencing Assay for Mutation Detection and Copy Number Analysis in Malignant Melanoma  Cynthia Spittle, M. Renee Ward, Katherine.
PIK3CA Hotspot Mutation Scanning by a Novel and Highly Sensitive High-Resolution Small Amplicon Melting Analysis Method  Panagiotis A. Vorkas, Nikoleta.
Development and Validation of a Template-Independent Next-Generation Sequencing Assay for Detecting Low-Level Resistance-Associated Variants of Hepatitis.
S. Hussain Askree, Shika Dharamrup, Lawrence N. Hjelm, Bradford Coffee 
Volume 24, Issue 4, Pages (July 2018)
Ashleigh C. McEvoy, Benjamin A. Wood, Nima M. Ardakani, Michelle R
Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT.
Volume 10, Issue 5, Pages (May 2012)
A Variant Detection Pipeline for Inherited Cardiomyopathy–Associated Genes Using Next-Generation Sequencing  Théo G.M. Oliveira, Miguel Mitne-Neto, Louise.
Accurate Detection of Copy Number Changes in DNA Extracted from Formalin-Fixed, Paraffin-Embedded Melanoma Tissue Using Duplex Ratio Tests  David A. Moore,
Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal- Finding Clinical Trial  Chih-Jian Lih, Robin D. Harrington, David.
A Clinically Validated Diagnostic Second-Generation Sequencing Assay for Detection of Hereditary BRCA1 and BRCA2 Mutations  Ian E. Bosdet, T. Roderick.
Volume 26, Issue 5, Pages (March 2016)
Low Incidence of Minor BRAF V600 Mutation-Positive Subclones in Primary and Metastatic Melanoma Determined by Sensitive and Quantitative Real-Time PCR 
A Pyrosequencing-Based Assay for the Rapid Detection of the 22q11
A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer  Zengliu Su, Dora Dias-Santagata,
Clinical Validation of a Next-Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-Related Genes  Rajesh R. Singh, Keyur P. Patel, Mark J.
Evaluation of High-Resolution Melting Analysis as a Diagnostic Tool to Detect the BRAF V600E Mutation in Colorectal Tumors  Martin Pichler, Marija Balic,
Nathan D. Montgomery, Sara R. Selitsky, Nirali M. Patel, D
Improved Detection of the KIT D816V Mutation in Patients with Systemic Mastocytosis Using a Quantitative and Highly Sensitive Real-Time qPCR Assay  Thomas.
HPV Genotype Detection Using Hybrid Capture Sample Preparation Combined with Whole Genome Amplification and Multiplex Detection with Luminex XMAP  Brian.
Multilaboratory Assessment of a New Reference Material for Quality Assurance of Cell- Free Tumor DNA Measurements  Hua-Jun He, Erica V. Stein, Yves Konigshofer,
Development of a Novel Next-Generation Sequencing Assay for Carrier Screening in Old Order Amish and Mennonite Populations of Pennsylvania  Erin L. Crowgey,
MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology  Lorenza Mittempergher, Leonie J.M.J. Delahaye,
Presentation transcript:

Plasmid-Based Materials as Multiplex Quality Controls and Calibrators for Clinical Next- Generation Sequencing Assays  David J. Sims, Robin D. Harrington, Eric C. Polley, Thomas D. Forbes, Michele G. Mehaffey, Paul M. McGregor, Corinne E. Camalier, Kneshay N. Harper, Courtney H. Bouk, Biswajit Das, Barbara A. Conley, James H. Doroshow, P. Mickey Williams, Chih-Jian Lih  The Journal of Molecular Diagnostics  Volume 18, Issue 3, Pages 336-349 (May 2016) DOI: 10.1016/j.jmoldx.2015.11.008 Copyright © 2016 Terms and Conditions

Figure 1 Design of control plasmids. A: Map of a representative control plasmid, pNF1_34041. Each control plasmid was constructed by inserting approximately 1000 bp of genomic DNA (blue box) spanning the mutation of interest (MOI) (red star). A 6-bp (ACATCG) molecular barcode (orange rectangle in B) was inserted near the MOI to track variant reads. Single-cut restriction sites are indicated by yellow triangles. B: Coordination of the molecular barcode with the MOI. A subset of sequencing reads from MOIs [an A deletion (red box)] and 6-bp molecular barcode confirms the mutation is plasmid borne. The Journal of Molecular Diagnostics 2016 18, 336-349DOI: (10.1016/j.jmoldx.2015.11.008) Copyright © 2016 Terms and Conditions

Figure 2 Control plasmid spiked-in genome (CPSG) titration workflow. Schematic showing the procedure for generating a CPSG sample. Briefly, plasmids are linearized, quantified, pooled, and spiked into a background genome at a determined copy number ratio. The Journal of Molecular Diagnostics 2016 18, 336-349DOI: (10.1016/j.jmoldx.2015.11.008) Copyright © 2016 Terms and Conditions

Figure 3 Parallel spike-in study strategy. A: Schematic diagram of parallel spike-in study. A pair of serially diluted sample sets made by spiking control plasmid pBRAF_476 or genomic DNA from cell line MALME-3M carrying the same BRAF V600E mutation, into the hapmap genomic DNA at the same titration points, followed by sequencing and regression analysis of the expected allele frequency versus the observed allele frequency. B: Scatterplot and regression analysis for pBRAF_476/MALME-3M and pAPC_18584/HCT-15. Linear regression models were fit for each. FFPE, formalin-fixed, paraffin-embedded; PGM, Personal Genome Machine; VAF, variant allele frequency. The Journal of Molecular Diagnostics 2016 18, 336-349DOI: (10.1016/j.jmoldx.2015.11.008) Copyright © 2016 Terms and Conditions

Figure 4 CPSG13 reproducibility during 18 months with three operators. A: CPSG13 was repeatedly sequenced by the National Cancer Institute's MPACT (NCI-MPACT) assay 90 times by three operators (OP1, OP2, and OP3) during an 18-month period. Boxplots showing the variant allele frequency (VAF) distribution binned by plasmid for each operator were plotted. The dashed line represents the 25% VAF point at which the plasmids were intended to be titrated. B: The mean VAF for each of the 13 plasmids and three operators was plotted as a green solid line during 18 months to evaluate the variability and stability of the material. The blue dashed line represents the expected 25% VAF. The red line represents a regression model through the series. The gray shadow represents the range of VAF for the 13 plasmids at each test date on the x axis. The Journal of Molecular Diagnostics 2016 18, 336-349DOI: (10.1016/j.jmoldx.2015.11.008) Copyright © 2016 Terms and Conditions

Figure 5 Comparison of the three CPSG51 data analysis pipelines. CPSG51 was sequenced by the National Cancer Institute's MPACT assay, and the same raw data were analyzed by Torrent Suite Software (TSS) versions 3.2.1, 4.0.2, and 4.4.2. Tile plots indicating whether a variant was detected (red box) or not (gray box) were generated for each of the three pipeline versions. Each row represents a mutation in a control plasmid, and each column represents a titration point. The plasmid name and the variant type (in parenthesis) are indicated on the left. HP, homopolymeric region; indel, insertion/deletion; SNV, single-nucleotide variant. The Journal of Molecular Diagnostics 2016 18, 336-349DOI: (10.1016/j.jmoldx.2015.11.008) Copyright © 2016 Terms and Conditions

Figure 6 Comparison of the three CPSG51 assay platforms. A 32-plasmid subset detectable across three different next-generation sequencing chemistries and platforms was compared. A tile plot was generated for each of the three platforms, and an indication was made as to whether the variant was detected (red box) or not (gray box). Each row represents a mutation in a control plasmid, and each column represents a titration point. The plasmid name and the variant type (in parenthesis) are indicated on the left. HP, homopolymeric region; indel, insertion/deletion; TSCA, TruSeq Custom Amplicon; SNV, single-nucleotide variant; WES, whole exome sequencing. The Journal of Molecular Diagnostics 2016 18, 336-349DOI: (10.1016/j.jmoldx.2015.11.008) Copyright © 2016 Terms and Conditions